Table 2.

Effect of Epadel on Risk of Major Coronary Events^a in JELIS and JELIS Substudies

Analysis Group	Cohort	N	HR (95% CI)	P Value	Reference
JELIS	All patients	18,645	0.81 (0.69–0.95)	0.011	Yokoyama, 2007 [36]
Impaired glucose metabolismb	All patients	4565	0.78 (0.60–0.998)	0.048	Oikawa, 2009 [46]
Peripheral artery disease	All patients	223	0.44 (0.19–0.97)	0.041	Ishikawa, 2010 [47]
JELIS	1° prevention	14,981	0.82 (0.63–1.06)	0.132	Yokoyama, 2007 [36]
TG ≥150 mg/dL and/or HDL-C <40 mg/dL	1° prevention	957	0.47 (0.23–0.98)	0.043	Saito, 2008 [45]
Patients not achieving LDL-C and non-HDL-C goalsc	1° prevention	6592	0.62 (0.43–0.88)	0.007	Sasaki, 2012 [48]
JELIS	2° prevention	3664	0.81 (0.657–0.998)	0.048	Yokoyama, 2007 [36]
Prior myocardial infarction	2° prevention	1050	0.73 (0.54–0.98)	0.033	Matsuzaki, 2009 [49]
Prior coronary intervention	2° prevention	895	0.65 (0.48–0.89)	0.007	Matsuzaki, 2009 [49]

CI confidence interval, HDL-C high-density lipoprotein cholesterol, HR hazard ratio, JELIS Japan EPA Lipid Intervention Study, LDL-C low-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, TG triglyceride

^aThe primary endpoint, major coronary events, consisted of sudden cardiac death, myocardial infarction, unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting [36]

^bDefined as fasting plasma glucose ≥110 mg/dL at study registration or after 6 months, physician-diagnosed diabetes mellitus, or use of antidiabetic drugs within first year of study [46]

^cLDL-C goal as recommended in 2007 Japanese Atherosclerosis Society guidelines and a non-HDL-C goal of 30 mg/dL higher than the LDL-C goal as recommended in Adult Treatment Panel III guidelines [48]